STUDY SEARCH RESULTS

1 study found for your search request:  3475-051

A Study of Pembrolizumab (MK-3475) in Pediatric Participants with an Advanced Solid Tumor or Lymphom...
Condition: Melanoma, Lymphoma, Solid tumor, Classical Hodgkin lymphoma, Microsatellite-instability-high solid tumor
Minimum Age: 6 months, Maximum Age: 17 years
Gender: Both
Study ID: NCT02332668
Status: Recruiting
Has Enrolling Locations in US or Canada




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site